PMID- 33157936
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 45
DP  - 2020 Nov 6
TI  - The efficacy of baroreflex activation therapy for heart failure: A meta-analysis 
      of randomized controlled trials.
PG  - e22951
LID - 10.1097/MD.0000000000022951 [doi]
LID - e22951
AB  - INTRODUCTION: The efficacy of baroreflex activation therapy for heart failure is 
      elusive. This meta-analysis aims to evaluate the impact of baroreflex activation 
      therapy on treatment efficacy of heart failure. METHODS: Several databases 
      including PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases 
      have been searched, and we include randomized controlled trials (RCTs) regarding 
      the efficacy of baroreflex activation therapy for patients with heart failure. 
      RESULTS: This meta-analysis includes 4 RCTs. Baroreflex activation therapy shows 
      significantly positive impact on the quality of life score (standard mean 
      difference SMD = -4.61; 95% confidence interval CI = -6.24 to -2.98; P < .00001), 
      6-minute hall walk (6MHW) distance (SMD = 2.83; 95% CI = 1.44- 4.22; P < .0001), 
      New York Heart Association (NYHA) Class (SMD = -3.23; 95% CI = -4.76 to -1.69; 
      P < .0001), N-terminal pro-brain natriuretic peptide (NT-proBNP) (SMD = -1.24; 
      95% CI = -1.58 to -0.89; P < .00001) and the duration of hospitalization 
      (SMD = -1.65; 95% CI = -2.90 to -0.39; P = .01) compared with control group for 
      heart failure, but has no obvious effect on left ventricular ejection fraction 
      (LVEF) (SMD = 1.43; 95% CI = -0.15-3.01; P = .08), or the number of 
      hospitalization per year (SMD = -1.17; 95% CI = -2.56-0.22; P = .10). 
      CONCLUSIONS: Baroreflex activation therapy can improve the treatment efficacy for 
      heart failure.
FAU - Cai, Guoqiang
AU  - Cai G
AD  - Department of Cardiology, Dianjiang Traditional Chinese Medicine Hospital, 
      Dianjiang.
FAU - Guo, Kai
AU  - Guo K
AD  - Department of Cardiology, Dianjiang Traditional Chinese Medicine Hospital, 
      Dianjiang.
FAU - Zhang, Dongyin
AU  - Zhang D
AD  - Department of Cardiology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, PR China.
FAU - Qin, Shu
AU  - Qin S
AD  - Department of Cardiology, The First Affiliated Hospital of Chongqing Medical 
      University, Chongqing, PR China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - *Baroreflex
MH  - *Electric Stimulation Therapy
MH  - Heart Failure/*therapy
MH  - Humans
MH  - Implantable Neurostimulators
MH  - Length of Stay
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Walk Test
PMC - PMC7647578
COIS- The authors declare that they have no competing interests.
EDAT- 2020/11/08 06:00
MHDA- 2020/11/24 06:00
PMCR- 2020/11/06
CRDT- 2020/11/07 01:02
PHST- 2020/11/07 01:02 [entrez]
PHST- 2020/11/08 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2020/11/06 00:00 [pmc-release]
AID - 00005792-202011060-00030 [pii]
AID - MD-D-18-07860 [pii]
AID - 10.1097/MD.0000000000022951 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Nov 6;99(45):e22951. doi: 10.1097/MD.0000000000022951.